Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 14/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1647415 | 0.88 | PTGER1 (0.59) | CCR5PTGER1LRRK2 | |
| SCHEMBL1647367 | 0.86 | LRRK2 (0.59) | MEN1KMT2APTGER1LRRK2 | |
| SCHEMBL2927947 | 0.84 | ALDH1A1 (0.56) | MEN1KMT2ACCR5PTGER1MAOB | |
| SCHEMBL5628945 | 0.81 | PTGER1 (0.52) | CCR5PTGER1MTNR1BMAOB | |
| SCHEMBL1648521 | 0.81 | LRRK2 (0.56) | MEN1KMT2ACCR5PTGER1LRRK2 | |
| SCHEMBL1646919 | 0.78 | PTGER1 (0.52) | MEN1KMT2APTGER1LRRK2 | |
| SCHEMBL1646587 | 0.78 | LRRK2 (0.60) | LRRK2MAOB | |
| SCHEMBL1646590 | 0.76 | LRRK2 (0.58) | MEN1KMT2ACCR5PTGER1LRRK2 | |
| SCHEMBL1648024 | 0.76 | LRRK2 (0.59) | MEN1KMT2APTGER1LRRK2 | |
| SCHEMBL5096177 | 0.76 | CCR5 (0.55) | CCR5PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483254-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2014-08-13 | — | — | EP | disclosed |
| US-8778939-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| EP-2483254-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184553-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-07-19 | — | — | US | disclosed |
| WO-2011038572-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184553-A1 | NOVEL COMPOUNDS | LRRK2, PARK7, PINK1 | MEN1 4102/4885KMT2A 2336/4885CCR5 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.